If we are to minimize the now well-documented burdens of COVID-19 on cancer patients, governments must support innovations that improve their outcomes and cut through the healthcare roadblocks posed by the pandemic.

In this exclusive interview, Dr. Huntsman discusses the elements of precision medicine that have contributed to its growth in oncology, some of the setbacks regarding its integration, and areas of research that have the potential to propel precision medicine to the next tier of scientific discovery and application.

Funding comes after the company meets key milestones with new collaborations and studies, product enhancements, and reimbursement progress.

A consortium led by Vancouver-based Canexia Health (formerly Contextual Genomics) will enable access to critical testing and treatment options for Canadian cancer patients during the COVID-19 pandemic.

Contextual Genomics and Eastern Ontario Regional Laboratory Association, a nonprofit organization offering high quality, patient focused, hospital-based lab services in Eastern Ontario, announced that they have partnered to bring Contextual Genomics’ ctDNA cancer genomic testing to EORLA’s Champlain Local Health Integration Network of Eastern Ontario, Canada.

Contextual Genomics and Lab Genomics, a personalized medicine company providing state of the art molecular genetic testing in Southern California, announced that they have signed an agreement enabling Lab Genomics to offer Contextual Genomics’ quality assured Next Generation Sequencing based ctDNA cancer genomic testing to patients in Southern California and other parts of the United States.

Contextual Genomics announced that it has named Brady Davis to its executive team. Mr. Davis, a veteran of the life sciences, healthcare and software industries, joins as Senior Vice President, Business Development of the Company, responsible for global strategy and business development.